The approval was based on results from CodeBreaK 300, a phase 3, multicenter, open-label, randomized trial that enrolled 160 patients who had not had previous treatment with a KRAS G12C inhibitor.

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

also known as sotorasib, will be indicated in the U.S. with Amgen’s (NASDAQ:AMGN) epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) as a late-line option for KRAS G12C ...

If it makes it through to market, UA022 would follow in the footsteps of pioneering KRAS inhibitors Amgen’s Lumakras (sotorasib) and Mirati’s Krazati (adagrasib), which have been approved as ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The CodeBreaK 300 clinical trial compared ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...